5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis
Key Takeaways
- In purulent skin and soft tissue infections (abscesses, furuncles), incision and drainage (I&D) is the primary definitive therapy; adjunctive antimicrobials are indicated only with extensive surrounding cellulitis, systemic toxicity, age <6 months, or immunocompromise.
- Clindamycin is an effective oral/IV agent for pediatric CA-MRSA only if the D-zone test is negative; a positive D-test indicates inducible macrolide-lincosamide-streptogramin B (iMLSb) resistance encoded by the erm gene, leading to rapid clinical failure under clindamycin therapy.
- Trimethoprim-sulfamethoxazole (dosed 8-12 mg/kg/day of TMP component divided BID) provides potent CA-MRSA activity but lacks dependable activity against Streptococcus pyogenes (Group A Strep) due to extracellular thymidine salvage, precluding its use as monotherapy for non-purulent cellulitis.
- Kingella kingae is a prominent cause of septic arthritis and osteomyelitis in children younger than 4 years; it is intrinsically resistant to clindamycin and vancomycin, requiring empiric coverage with a beta-lactam (cefazolin, ampicillin, or ceftriaxone).
- Transition from IV to oral therapy in uncomplicated pediatric acute hematogenous osteomyelitis (AHO) is indicated when the patient is afebrile for 24-48 hours, exhibits clinical symptom improvement, and achieves a >=50% reduction in CRP from peak, with total duration of 3-4 weeks for AHO and 2-3 weeks for septic arthritis.
5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis
Quick Answer: Pediatric purulent SSTIs (abscesses) require incision and drainage (I&D) as primary therapy, with antibiotics reserved for surrounding cellulitis, systemic symptoms, or age <6 months. When treating suspected CA-MRSA, clindamycin (30–40 mg/kg/day) is effective only if the D-zone test is negative (ruling out inducible $i\text{MLS}_B$ resistance). TMP-SMX (8–12 mg/kg/day TMP component BID) covers MRSA but fails to cover Group A Streptococcus (GAS); doxycycline (4 mg/kg/day BID) is safe for short courses (≤21 days) regardless of age per updated AAP guidance. For osteomyelitis and septic arthritis in children <4 years, always include a beta-lactam (cefazolin) because Kingella kingae is intrinsically resistant to clindamycin and vancomycin. Transition to oral therapy once afebrile for 24–48 hours with ≥50% CRP reduction, treating for 3–4 weeks (osteomyelitis) or 2–3 weeks (septic arthritis).
1. Pediatric SSTIs: Non-Purulent vs Purulent Infections
The Infectious Diseases Society of America (IDSA) guidelines categorize skin and soft tissue infections (SSTIs) into non-purulent and purulent forms to streamline pathogen prediction and antimicrobial selection.
+-----------------------------------------------------------------------------------------+
| Pediatric SSTI Classification & Management Algorithm |
+-----------------------------------------------------------------------------------------+
| Feature | Non-Purulent (Cellulitis, Erysipelas) | Purulent (Abscess, Carbuncle, Furuncle)|
|----------------------|---------------------------------------|---------------------------------------|
| Predominant Pathogen | Streptococcus pyogenes (GAS) > MSSA | Community-Acquired MRSA (CA-MRSA) > |
| | | MSSA |
| Clinical Signs | Diffuse spreading erythema, warmth, | Fluctuant, tender erythematous nodule |
| | edema, induration, NO fluctuance/pus | with purulent collection / drainage |
| Primary Intervention | Systemic Antimicrobials | INCISION AND DRAINAGE (I&D) |
| Mild / Outpatient Rx | Cephalexin: 50-100 mg/kg/day div TID | I&D ALONE if simple/small (<2 cm) and |
| | Cefadroxil: 30 mg/kg/day div BID | afebrile. If antibiotics indicated: |
| | Amox-clav: 45-90 mg/kg/day div BID | Clindamycin OR TMP-SMX |
| Severe / Inpatient Rx| Cefazolin: 50-100 mg/kg/day div Q8H | I&D + IV Vancomycin (40-60 mg/kg/d) |
| | Ampicillin-sulbactam: 150-200 mg/kg/d | OR IV Clindamycin (30-40 mg/kg/d) |
+-----------------------------------------------------------------------------------------+
The Incision and Drainage (I&D) Mandate
In purulent cutaneous abscesses, the primary determinant of cure is adequate mechanical evacuation of pus. Randomized controlled trials in children demonstrate that for small, uncomplicated abscesses (<2 cm in diameter) without surrounding erythema or systemic signs, I&D alone without antibiotics yields cure rates >90%. Antibiotics do not penetrate the necrotic, acidic, hypoperfused center of an intact abscess.
Indications for Adjunctive Antimicrobial Therapy After I&D
Systemic antibiotics should be added to I&D when any of the following are present:
- Severe or extensive disease (multiple sites of infection, abscess diameter ≥5 cm, or extensive surrounding cellulitis).
- Rapid progression or signs of systemic illness (fever, tachycardia, tachypnea, hypotension, toxicity).
- Patient age younger than 6 months (immature immune defenses and high risk of bacteremia).
- High-risk anatomical areas (face, hands, feet, perineum, genitalia) or areas difficult to drain.
- Associated septic thrombophlebitis or lack of response to I&D alone after 48 hours.
- Significant underlying host comorbidities (immunodeficiency, neutropenia, diabetes mellitus).
2. CA-MRSA Pharmacotherapy in Children
Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) typically harbors the small, mobile Staphylococcal Cassette Chromosome mec (SCCmec) type IV or V element and frequently produces the Panton-Valentine Leukocidin (PVL) pore-forming cytotoxin.
+-----------------------------------------------------------------------------------------+
| Oral Antimicrobial Regimens for Pediatric CA-MRSA SSTIs |
+-----------------------------------------------------------------------------------------+
| Antimicrobial | Pediatric Dosing | Spectrum & Key Clinical Nuances |
|-----------------|--------------------------------------|----------------------------------------|
| Clindamycin | 30 to 40 mg/kg/day divided TID | Covers CA-MRSA & GAS. Inhibits toxin |
| | (Max: 1800 mg/day; IV or oral) | production (PVL). MUST be D-test neg. |
| TMP-SMX | 8 to 12 mg/kg/day TMP component | High CA-MRSA potency. ZERO dependable |
| (Bactrim) | divided BID (Max: 320 mg TMP/day) | GAS coverage! Avoid in infants <2 mo. |
| Doxycycline | 4 mg/kg/day divided BID | CA-MRSA potency. AAP approved for |
| | (Max: 200 mg/day; age >=8 or <21 d) | short courses (<=21 days) at any age. |
| Linezolid | <12 yr: 30 mg/kg/day divided Q8H | Complete MRSA & GAS coverage; toxin |
| | >=12 yr: 20 mg/kg/day (600 mg) div Q12| inhibition. Risk of myelosuppression. |
+-----------------------------------------------------------------------------------------+
Clindamycin & The D-Zone Test Mechanics
Clindamycin binds the 50S ribosomal subunit to inhibit bacterial protein and toxin synthesis. Resistance in S. aureus occurs via two primary genetic mechanisms:
- Efflux pump (msrA gene): Active pumping of 14- and 15-membered macrolides (erythromycin, azithromycin) out of the cell. The isolate tests erythromycin-resistant but clindamycin-susceptible. Because clindamycin is not a substrate for this efflux pump, the drug remains clinically effective (D-zone test NEGATIVE).
- Ribosomal target modification (erm gene): The erm gene encodes an enzyme that methylates the 23S rRNA adenine residues on the 50S subunit, conferring cross-resistance to macrolides, lincosamides, and type B streptogramins ($i\text{MLS}_B$). In many isolates, this gene is inducible by erythromycin but not initially by clindamycin. Automated testing may report the isolate as clindamycin-susceptible.
+-----------------------------------------------------------------------------------------+
| D-Zone Test Interpretation & Action |
+-----------------------------------------------------------------------------------------+
| Erythromycin Disk | Clindamycin Disk | D-Zone Morphology | Phenotype & Action |
|-------------------|------------------|--------------------|-----------------------------|
| Resistant (R) | Susceptible (S) | Circular, circular | Efflux pump (msrA) |
| | | zone of inhibition | D-Test NEGATIVE: Use Clinda |
| Resistant (R) | Susceptible (S) | Blunted, flat zone | Inducible iMLSb (erm gene) |
| | | resembling a "D" | D-Test POSITIVE: AVOID |
| | | adjacent to Erythro| Clinda (Rapid failure risk) |
+-----------------------------------------------------------------------------------------+
Board Exam Rationale: Under clindamycin monotherapy, an $i\text{MLS}_B$-positive strain undergoes spontaneous point mutations (at a rate of $\sim 10^{-7}$) that convert inducible resistance into constitutive resistance, leading to rapid clinical treatment failure. If the D-test is positive, clindamycin is strictly contraindicated.
Trimethoprim-Sulfamethoxazole (TMP-SMX) & The GAS Coverage Void
TMP-SMX is dosed based on its trimethoprim component: 8 to 12 mg/kg/day divided every 12 hours. While TMP-SMX is highly active against CA-MRSA, it lacks reliable activity against Streptococcus pyogenes (Group A Streptococcus) in vivo. In infected, purulent tissues, S. pyogenes can utilize extracellular thymidine and purines released from lysed human leukocytes, completely bypassing the TMP-SMX block on tetrahydrofolic acid synthesis. Therefore, TMP-SMX should never be used as monotherapy for non-purulent cellulitis. If mixed MRSA and GAS infection is suspected, TMP-SMX must be combined with a beta-lactam (e.g., cephalexin).
Doxycycline in Pediatrics: The Removal of the 8-Year Age Restriction
Tetracyclines historically carried a black-box contraindication in children younger than 8 years due to permanent dental staining and enamel hypoplasia. However, extensive pediatric research and updated American Academy of Pediatrics (AAP) Red Book guidance establish that doxycycline binds calcium far less avidly than older tetracyclines (tetracycline, minocycline). Multiple prospective studies demonstrated that short courses (≤21 days) of doxycycline do NOT cause dental discoloration or enamel defects in children under 8 years. Doxycycline (4 mg/kg/day divided BID, max 200 mg/day) is endorsed for short-term CA-MRSA or tick-borne infections across all pediatric age cohorts.
3. Pediatric Acute Hematogenous Osteomyelitis (AHO) & Septic Arthritis
Musculoskeletal infections in children are predominantly hematogenous in origin. Sluggish, turbulent capillary loops in the metaphyses of growing long bones (femur, tibia, humerus) create a fertile nidus for bacterial deposition and micro-infarction.
+-----------------------------------------------------------------------------------------+
| Microbiology of Pediatric Osteomyelitis & Septic Arthritis |
+-----------------------------------------------------------------------------------------+
| Age Group | Predominant Pathogens | Clinical & Microbiological Pearls |
|---------------------------|---------------------------------|-----------------------------------|
| All pediatric ages | Staphylococcus aureus | Most common overall (>70-80%). |
| | (MSSA and CA-MRSA) | PVL+ strains cause severe osteo. |
| Children < 4 years | Kingella kingae | Fastidious Gram-negative coccobacillus|
| (Especially 6 to 36 mo) | | INTRINSICALLY RESISTANT to |
| | | clindamycin and vancomycin! |
| All ages | Streptococcus pyogenes (GAS) | Highly destructive, high CRP. |
| Sickle Cell Disease | Salmonella species & S. aureus | Bone marrow microvascular hypoxia |
| | | predisposes to Salmonella seeding.|
| Neonates (< 1 month) | Group B Strep, E. coli, MSSA/MRSA| High rate of concomitant arthritis|
+-----------------------------------------------------------------------------------------+
The Infant Transphyseal Bridge
In infants younger than 18 months, transphyseal blood vessels penetrate the cartilaginous growth plate, bridging the metaphysis directly to the epiphysis and the intra-articular joint space. Consequently, acute hematogenous osteomyelitis in infants frequently decompresses directly into the joint space, resulting in concurrent septic arthritis and permanent epiphyseal plate damage.
Kingella kingae: The Stealth Pathogen of Toddlers
Kingella kingae colonizes the respiratory tract and translocates into bones and joints in toddlers aged 6 months to 4 years:
- Clinical Presentation: Often subacute and insidious—mild limp, joint swelling, low-grade or absent fever, and modest elevations in inflammatory markers (ESR, CRP).
- Culture-Negative Arthritis: K. kingae is fastidious and does not grow well on standard solid agar; clinical diagnosis requires inoculating synovial fluid directly into blood culture vials or performing specific real-time PCR or 16S rRNA assays.
- Pharmacological Achilles Heel: Kingella kingae is intrinsically resistant to both clindamycin and vancomycin! However, it is exquisitely susceptible to beta-lactams (ampicillin, cefazolin, cephalexin, ceftriaxone). If a toddler with septic arthritis is treated with vancomycin or clindamycin alone, K. kingae will not be treated, resulting in clinical failure.
4. Empiric Regimens, Transition Criteria & Durations for AHO
+-----------------------------------------------------------------------------------------+
| Empiric IV Antimicrobial Selection for AHO / Septic Arthritis |
+-----------------------------------------------------------------------------------------+
| Clinical Scenario | Empiric Parenteral Regimen |
|------------------------------------------|----------------------------------------------|
| Age >=4 yr, Low Local MRSA (<10-15%) | Cefazolin: 100-150 mg/kg/day divided Q8H |
| | (Max: 6000 mg/day or 6 g/day) |
| Age >=4 yr, High Local MRSA (>=10-15%) | Vancomycin: 60 mg/kg/day divided Q6-8H |
| or Septic Presentation | OR Clindamycin: 40 mg/kg/day divided Q8H |
| Age <4 years (MUST cover Kingella kingae)| Cefazolin PLUS Vancomycin (or Clindamycin) |
| | OR Ampicillin-sulbactam: 150-200 mg/kg/d Q6H |
| Sickle Cell Disease (Salmonella + MRSA) | Ceftriaxone: 50-75 mg/kg/d once daily PLUS |
| | Vancomycin: 60 mg/kg/day divided Q6-8H |
+-----------------------------------------------------------------------------------------+
Evidence-Based IV-to-Oral Transition Criteria
Pediatric Infectious Diseases Society (PIDS) and IDSA guidelines strongly recommend early transition from IV to oral antimicrobials rather than placing peripherally inserted central catheters (PICCs) for prolonged outpatient parenteral antibiotic therapy (OPAT), which carries high rates of mechanical malfunction, thrombosis, and catheter infections.
+-----------------------------------------------------------------------------------------+
| PIDS/IDSA Criteria for Early IV-to-Oral Step-Down |
+-----------------------------------------------------------------------------------------+
| Criterion 1 | Afebrile for at least 24 to 48 hours without antipyretics. |
| Criterion 2 | Significant clinical improvement: resolving pain, swelling, warmth, and |
| | restoration of limb motion or weight-bearing ability. |
| Criterion 3 | Objective biomarker reduction: C-reactive protein (CRP) has decreased by |
| | AT LEAST 50% from the peak baseline value. |
| Criterion 4 | Patient can swallow, retain, and absorb high-dose oral medications. |
| Criterion 5 | An appropriate oral agent with proven pathogen susceptibility exists. |
+-----------------------------------------------------------------------------------------+
Oral Step-Down Regimens & Durations
- MSSA / K. kingae: High-dose oral cephalexin (100–150 mg/kg/day divided TID or QID, max 4 g/day).
- CA-MRSA: High-dose oral clindamycin (30–40 mg/kg/day divided TID, if D-test negative) OR oral linezolid.
- K. kingae (confirmed): Oral amoxicillin (80–90 mg/kg/day divided TID) or cephalexin.
- Treatment Durations:
- Uncomplicated Acute Hematogenous Osteomyelitis: 3 to 4 weeks total (IV + oral combined).
- Uncomplicated Septic Arthritis: 2 to 3 weeks total (IV + oral combined).
- Complicated Osteomyelitis (subperiosteal abscess, chronic osteo, surgical debridements): ≥6 weeks.
A 20-month-old child presents with a 4-day history of refusal to bear weight on the left leg, irritability, and a low-grade temperature of 38.0°C. Physical examination reveals left knee warmth and mild effusion without erythema. Synovial fluid aspiration yields 38,000 WBCs/mcL (72% PMNs), with no organisms on Gram stain. Real-time PCR confirms Kingella kingae. The resident physician plans to initiate IV vancomycin 60 mg/kg/day. What is the fundamental pharmacological flaw in this regimen, and what is the drug of choice?
A 14-year-old high school football player presents with a 4-cm fluctuant, tender, purulent cutaneous abscess on his right thigh surrounded by 3 cm of spreading erythema. Incision and drainage is performed, and cultures yield heavy growth of Staphylococcus aureus. Susceptibility testing reveals resistance to erythromycin and susceptibility to clindamycin. The microbiology laboratory reports a 'Positive D-Zone Test.' What is the clinical significance of this finding, and which antimicrobial management strategy is most appropriate?
An 8-year-old child is hospitalized with uncomplicated acute hematogenous osteomyelitis of the distal tibia caused by methicillin-susceptible Staphylococcus aureus (MSSA). The patient has received 72 hours of IV cefazolin (150 mg/kg/day). The child is now afebrile for 36 hours, reports marked resolution of bone pain, and is able to ambulate. Serum CRP has decreased from an admission peak of 7.6 mg/dL to 2.8 mg/dL. What is the most appropriate next step in antimicrobial management?